BACIL PHARMA LIMITED

Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327

Date: 12^{th} August, 2025

To,
The Manager Listing
Department **BSE**
Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort Mumbai-400001

Scrip Code: **524516**
Scrip Id: **BACPHAR**

Sub: Outcome of Board Meeting Held on August 12^{th}, 2025

Dear Sir,
Pursuant to provisions of Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. August 12, 2025 have discussed and approved the following key matters:

1. Unaudited Financial Results for the quarter ended 30^{th} June, 2025;

The Board has Approved the Audited Financial Results of the Company for the quarter ended 30^{th} June, 2025. The financial results will be submitted to the exchange and made available on the Company's website.

2. Approval of the Resignation of Manager

The Board has approved the resignation of the Manager of the Comapny Mr. Ganpat Dhondu Salekar.

The meeting of the Board of Directors commenced at 0 **6.00P.M**. and concluded at **0 6 : 4 0 P.M.**
The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.
Submission for information and necessary update. Kindly take the above on your record.

Thanking you,
Yours faithfully,

For Bacil Pharma Limited

Shah
Chaitali
Kalpataru

Digitally signed by Shah Chaitali Kalpataru
Date: 2025.08.12
18:49:28 +05'30'

Ms. Chaitali Kalpataru Shah
Director & CFO
DIN: 11167778

BACIL PHARMA LIMITED

CIN : {L24200MH1987PLC043427}

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-
	Other income	100.25	8.77	1.08	66.14
	Total revenue	**100.25**	**8.77**	**1.08**	**66.14**
2	**Expenses**				
	Employee benefits expense	2.95	3.71	2.40	13.84
	Depreciation and amortization expense	-	-	0.04	0.07
	Other expenses	7.94	3.51	2.04	11.47
	Total expenses	**10.89**	**7.22**	**4.47**	**25.39**
3	**Profit before exceptional items and tax**	**89.36**	**1.56**	**(3.39)**	**40.76**
	Exceptional items	-	-	-	-
	Profit / (Loss) from ordinary activities before tax	**89.36**	**1.56**	**(3.39)**	**40.76**
4	**Tax expense:**				
	Current Tax	**(22.49)**	-	-	-
	Deferred tax	-	-	(0.00)	(0.34)
5	**Profit/(Loss) from ordinary activities after tax**	**66.87**	**1.56**	**(3.40)**	**40.41**
6	**Other Comprehensive Income (OCI)**				
	Item that will not be reclassified to profit or loss				
	Gain/(Loss) on recognised on fair valuation of Financial Assets	8.55	(5.84)	33.30	(0.49)
	Income tax relating to these items	(2.22)	1.52	(8.66)	0.13
	Total	**6.33**	**(4.32)**	**24.64**	**(0.36)**
	Reclassification of loss on asset held for sale	-	-	-	-
	Total Other Comprehensive Income (OCI)	**6.33**	**(4.32)**	**24.64**	**(0.36)**
	Profit/(Loss) for the Period	**73.20**	**(2.77)**	**21.25**	**40.05**
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,397.03	1,397.02	589.00	1,397.02
7	**Earning Per Share (EPS) (Not annualised)**				
	(1) Basic	0.48	0.02	(0.06)	0.64
	(2) Diluted	0.48	0.02	(0.06)	0.64

Notes:

1. The Above Financial Results were reviewed by the audit committee of the board on and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind As notified under the companies (Accounting Standards) Rule 2015.
2. Figures for the corresponding quarter ended i.e. 31st March 2025 in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.
3. The Company has single business segment therefore in the context of Ind As 108, disclosure of segement information is not applicable.
4. Previous quarter figures have been regrouped /reclassified whereever necessary, to make them comparable.

FOR BACIL PHARMA LIMITED

Shah Chaitali Kalpataru

Digitally signed by Shah Chaitali Kalpataru
Date: 2025.08.12 18:44:41 +05'30'

Chaitali Kalpataru Shah
Director
DIN: 11167778

Date:
Place: Mumbai

LAXMIKANT KABRA & CO LLP
Chartered Accountants

604, Centrum, Opp. TMC Office, Near
Wagle Estate, Thane (W) 400 604
022 2539 0009
+91 62629 18282
lkk@laxmikantkabra.com

Independent Auditor's Review Report on the Quarter Ended 30th June 2025 Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors
BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the Quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. Company's Board of Directors responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Emphasis of Matter

The Company has raised funds through preferential allotment. In the absence of adequate documentation and explanations from management, we are unable to verify their application and end use. Due to lack of complete information and confirmations from management, we are unable to determine whether certain transactions during the quarter are with related parties and, if so, whether they are at arm's length. In the absence of sufficient documentation regarding advances/deposits given during the quarter, we are unable to comment on their nature, purpose, recoverability, and compliance with applicable provisions.

5. **Other Matter**

   The Company has recognized commission income during the period under "Other Income." While statutory dues such as GST and TDS have been verified as deposited based on documents provided by management, we were not given access to the counterparty or the original underlying contract. Our verification is therefore limited to the records and explanations provided by management.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Laxmikant Kabra & Co LLP
Chartered Accountants
Firm Reg. No.: 117183W/ W100736

LAXMIKANT KABRA & CO LLP FRN-W100736/117183W CA THANE (W) 400604 CHARTERED ACCOUNTANTS

CA Siddhant Kabra
Partner
Membership No.: 193348

Place: Thane
Date: 12/08/2025

UDIN: 25193348BMHXXQ5120